-
公开(公告)号：US20240342144A1
公开(公告)日：2024-10-17
申请号：US18750014
申请日：2024-06-21
Applicant: Deciphera Pharmaceuticals, LLC
Inventor： Rodrigo Ruiz Soto , Oliver Rosen , Jama Pitman
IPC: A61K31/4375 , A61K31/4745 , A61P9/12 , A61P35/00
CPC classification number: A61K31/4375 , A61K31/4745 , A61P9/12 , A61P35/00
Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240335533A1
公开(公告)日：2024-10-10
申请号：US18757437
申请日：2024-06-27
Applicant: Astellas Pharma Inc. , TRON - Translationale Onkologie an der Universitätismedizin der Johannes Gutenberg-Universtät Mainz
Inventor： Ugur Sahin , Özlem Türeci , Rita Mitnacht-Kraus , Stefan Denis Jacobs , Magdalena Jadwiga Utsch , Cornelia Adriana Maria Heinz , Christiane Regina Stadler
IPC: A61K39/395 , A61K31/282 , A61K31/337 , A61K31/4375 , A61K31/513 , A61K31/519 , A61K31/675 , A61K31/704 , A61K33/243 , A61K38/20 , A61K45/06 , C07K16/30
CPC classification number: A61K39/39558 , A61K31/282 , A61K31/337 , A61K31/4375 , A61K31/513 , A61K31/519 , A61K31/675 , A61K31/704 , A61K33/243 , A61K38/2013 , A61K45/06 , C07K16/30 , C07K16/3046 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/734
Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
-
公开(公告)号：US20240335432A1
公开(公告)日：2024-10-10
申请号：US18294079
申请日：2022-09-02
Applicant: JCR PHARMACEUTICALS CO., LTD. , ARMAGEN, INC.
Inventor： Mathias SCHMIDT
IPC: A61K31/4375 , A61P25/28
CPC classification number: A61K31/4375 , A61P25/28
Abstract: [Problem to be solved] To provide a therapeutic compound for neuronal ceroid lipofuscinosis. [Solution] Provided is a compound for treatment and/or prevention of neuronal ceroid lipofuscinosis represented by the following general formula [I]. In the general formula [I]. R1 is a methyl group or a hydroxymethyl group, R2 is a methyl group or a hydroxymethyl group, R3 is one of a hydroxy group, a methoxy group, an ethoxy group, an isopropoxy group, a methoxyethoxy group, a methoxypropoxy group, or an ethoxypolopoxy group, and R4 is one of a hydroxy group. a methoxy group, an ethoxy group, an isopropoxy group, a methoxyethoxy group, a methoxypropoxy group, or an ethoxypolopoxy group, In particular, provided is a compound represented by the general formula [I] with R1 being a methyl group, R2 being a methyl group, R3 being a hydroxy group, and R4 being a methoxyethoxy group.
-
公开(公告)号：US20240327408A1
公开(公告)日：2024-10-03
申请号：US18579501
申请日：2022-07-14
Applicant: CHINA PHARMACEUTICAL UNIVERSITY
Inventor： Haiying SUN , Yibei XIAO , Yuantao FU , Rongliang TAN , Guangjun XIE , Jinxin JIANG , Yinan YUAN
IPC: C07D471/14 , A61K31/4375 , A61K31/444 , A61K31/4745 , A61K31/519 , A61P35/02 , C07D471/04 , C07D491/147 , C07D495/14 , C07D513/14
CPC classification number: C07D471/14 , A61K31/4375 , A61K31/444 , A61K31/4745 , A61K31/519 , A61P35/02 , C07D471/04 , C07D491/147 , C07D495/14 , C07D513/14
Abstract: The present invention is related to compounds of formula I containing a tetrahydronaphthyridinone or tetrahydropyridopyrimidinone skeleton and preparation methods therefor. It has been experimentally verified that the compounds containing a tetrahydronaphthyridinone or tetrahydropyridopyrimidinone skeleton have significant agonistic effects on caseinolytic protease P (ClpP), and can be applied in the treatment of various cancers.
-
公开(公告)号：US12102620B2
公开(公告)日：2024-10-01
申请号：US16943871
申请日：2020-07-30
Applicant: Deciphera Pharmaceuticals, LLC
Inventor： Daniel L. Flynn , Bryan D. Smith , Anu Gupta
IPC: A61K31/4375 , A61K31/4184 , A61K31/4439 , A61K31/4523 , A61K31/506 , A61K31/519 , A61K45/06 , A61P43/00
CPC classification number: A61K31/4375 , A61K31/4184 , A61K31/4439 , A61K31/4523 , A61K31/506 , A61K31/519 , A61K45/06 , A61P43/00
Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20240317735A1
公开(公告)日：2024-09-26
申请号：US18016289
申请日：2021-07-12
Applicant: Hoffmann-La Roche Inc.
Inventor： Fabian DEY , Xiaoqing WANG , Zhisen ZHANG , Wei ZHU
IPC: C07D471/04 , A61K31/4375 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/5377 , A61K31/5386 , C07D519/00
CPC classification number: C07D471/04 , A61K31/4375 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/5377 , A61K31/5386 , C07D519/00
Abstract: The present invention relates to compounds of formula (I),
wherein R1, R2, R3a, R3b, R4, Q, Z and Y are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.-
公开(公告)号：US20240315994A1
公开(公告)日：2024-09-26
申请号：US18441446
申请日：2024-02-14
Applicant: ARPEGGIO BIOSCIENCES, INC.
Inventor： Timothy READ , Zoe WINIGRAD , Ardeshir GOLIAEI , Joseph AZOFEIFA , John K. DICKSON , Jason R. HARRIS , Eric MARTIN
IPC: A61K31/167 , A61K31/16 , A61K31/192 , A61K31/277 , A61K31/341 , A61K31/351 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/425 , A61K31/426 , A61K31/428 , A61K31/433 , A61K31/435 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/44 , A61K31/4439 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/4985 , A61K31/505 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/538 , A61K31/5415 , C07C233/06 , C07D217/18 , C07D217/20 , C07D239/545 , C07D265/36 , C07D279/16 , C07D471/04 , C07D487/04
CPC classification number: A61K31/167 , A61K31/16 , A61K31/192 , A61K31/277 , A61K31/341 , A61K31/351 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/425 , A61K31/426 , A61K31/428 , A61K31/433 , A61K31/435 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/44 , A61K31/4439 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/4985 , A61K31/505 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/538 , A61K31/5415 , C07C233/06 , C07D217/18 , C07D217/20 , C07D239/545 , C07D265/36 , C07D279/16 , C07D471/04 , C07D487/04
Abstract: Provided herein are inhibitors of GPX4, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the GPX4 inhibitory compounds for the modulation of ferroptosis and treatment of disease.
-
公开(公告)号：US20240287062A1
公开(公告)日：2024-08-29
申请号：US18559317
申请日：2022-05-06
Applicant: Enliven Inc.
Inventor： Joseph P. LYSSIKATOS , Li REN , Samuel KINTZ
IPC: C07D471/04 , A61K31/4375 , A61K31/444 , A61P35/00
CPC classification number: C07D471/04 , A61K31/4375 , A61K31/444 , A61P35/00
Abstract: The present disclosure relates to compounds and compositions for inhibition of RAF serine/threonine protein kinases and inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as melanoma, non-small cell lung cancer, and chronic myeloid leukemia (CML).
-
公开(公告)号：US20240287058A1
公开(公告)日：2024-08-29
申请号：US17921580
申请日：2021-04-29
Applicant: Relay Therapeutics, Inc. , D. E. Shaw Research, LLC
Inventor： Alessandro BOEZIO , Lucian V. DIPIETRO , Cary Griffin FRIDRICH , Hakan GUNAYDIN , Ravi KURUKULASURIYA , André LESCARBEAU , Mary M. MADER , Thomas H. MCLEAN , Levi CharlesThomas PIERCE , Kevin David RAYNOR , Kelley C. SHORTSLEEVES , Yong TANG , Alexander M. TAYLOR , W. Patrick WALTERS , Hanmo ZHANG , Fabrizio GIORDANETTO , Yakov PECHERSKY , Qi WANG , Bren-Jordan ATIENZA , Megan BERTRAND-LAPERLE , Andrew J. BURNIE , Fei CHEN , Sampada CHITALE , Shorena GELOZIA , Jean-Benoit GIGUERE , Elodie LANDAGARAY , Alexandre LARIVEE , Thomas LEPITRE , Gaetan MAERTENS , Johanne OUTIN , Mohan PAL , Claudio STURINO , Kashif TANVEER , Rakesh THORAT , Naresh VEMULA , Elaine B. KRUEGER , Yue PAN , Michael Paul DENINNO , Yves BOUSQUET , Antoine JOBIN-DES LAURIERS , Jessica LEE , Tarek MOHAMED
IPC: C07D471/04 , A61K31/4035 , A61K31/404 , A61K31/4155 , A61K31/416 , A61K31/428 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/472 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/536 , A61K31/69 , C07D209/46 , C07D209/48 , C07D217/24 , C07D231/56 , C07D239/82 , C07D265/18 , C07D275/06 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/06 , C07D409/12 , C07D409/14 , C07D417/12 , C07D487/04 , C07D519/00 , C07F5/02
CPC classification number: C07D471/04 , A61K31/4035 , A61K31/404 , A61K31/4155 , A61K31/416 , A61K31/428 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/472 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/536 , A61K31/69 , C07D209/46 , C07D209/48 , C07D217/24 , C07D231/56 , C07D239/82 , C07D265/18 , C07D275/06 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/06 , C07D409/12 , C07D409/14 , C07D417/12 , C07D487/04 , C07D519/00 , C07F5/025
Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-α enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-α signaling with the compounds and compositions of the disclosure.
-
公开(公告)号：US12059464B2
公开(公告)日：2024-08-13
申请号：US17008316
申请日：2020-08-31
Applicant: Astellas Pharma Inc. , TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH
Inventor： Ugur Sahin , Ozlem Tureci , Rita Mitnacht-Kraus , Stefan Denis Jacobs , Magdalena Jadwiga Utsch , Cornelia Adriana Maria Heinz , Christiane Regina Stadler
IPC: A61K39/395 , A61K31/282 , A61K31/337 , A61K31/4375 , A61K31/513 , A61K31/519 , A61K31/675 , A61K31/704 , A61K33/243 , A61K38/20 , A61K45/06 , C07K16/30
CPC classification number: A61K39/39558 , A61K31/282 , A61K31/337 , A61K31/4375 , A61K31/513 , A61K31/519 , A61K31/675 , A61K31/704 , A61K33/243 , A61K38/2013 , A61K45/06 , C07K16/30 , C07K16/3046 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/734 , A61K39/39558 , A61K2300/00
Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
-
-
-
-
-
-
-
-
-
Search Results
2004
records
(took 0.022 seconds)
